Compare RSI & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSI | PBLS |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 2020 | 2026 |
| Metric | RSI | PBLS |
|---|---|---|
| Price | $31.32 | $30.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $28.20 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 502.7K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 933.33 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,134,428,000.00 | N/A |
| Revenue This Year | $25.44 | N/A |
| Revenue Next Year | $14.27 | N/A |
| P/E Ratio | $391.50 | ★ N/A |
| Revenue Growth | ★ 22.76 | N/A |
| 52 Week Low | $15.18 | $25.56 |
| 52 Week High | $34.53 | $33.65 |
| Indicator | RSI | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 56.52 |
| Support Level | $25.56 | $26.83 |
| Resistance Level | N/A | $33.65 |
| Average True Range (ATR) | 1.24 | 2.62 |
| MACD | -0.38 | 0.14 |
| Stochastic Oscillator | 17.08 | 63.76 |
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.